UY36664A - Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro - Google Patents

Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro

Info

Publication number
UY36664A
UY36664A UY0001036664A UY36664A UY36664A UY 36664 A UY36664 A UY 36664A UY 0001036664 A UY0001036664 A UY 0001036664A UY 36664 A UY36664 A UY 36664A UY 36664 A UY36664 A UY 36664A
Authority
UY
Uruguay
Prior art keywords
preparation
chlorophenyl
methyl
monohidrocloruro
dician
Prior art date
Application number
UY0001036664A
Other languages
English (en)
Inventor
Dr Franz-Josef Mais
Dr Britta Olenik
Dr Werner Heilmann
Keil Brigit
Becker Guido
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY36664A publication Critical patent/UY36664A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente solicitud se refiere a un procedimiento nuevo y mejorado para la preparación del compuesto 2- {4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4- 5 il]fenoxi}etil-L-alanil-L-alaninato-monohidrocloruro de la fórmula (I),nuevas fases previas para su preparación y la preparación y uso de la modificación cristalina I de 2-{4-[2-({[2- (4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-L-alanil-Lalaninato-monohidrocloruro de la fórmula (I).
UY0001036664A 2015-05-06 2016-05-02 Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro UY36664A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166606 2015-05-06
EP15192030 2015-10-29

Publications (1)

Publication Number Publication Date
UY36664A true UY36664A (es) 2016-11-30

Family

ID=55969107

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036664A UY36664A (es) 2015-05-06 2016-05-02 Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro

Country Status (32)

Country Link
US (1) US20180155336A1 (es)
EP (1) EP3292133B1 (es)
JP (1) JP2018516882A (es)
KR (1) KR20180002698A (es)
CN (1) CN107531688A (es)
AU (1) AU2016268920A1 (es)
BR (1) BR112017023852A2 (es)
CA (1) CA2984984A1 (es)
CL (1) CL2017002764A1 (es)
CO (1) CO2017011294A2 (es)
CU (1) CU20170136A7 (es)
DK (1) DK3292133T3 (es)
EA (1) EA201792422A1 (es)
EC (1) ECSP17072780A (es)
ES (1) ES2744227T3 (es)
HK (1) HK1246290A1 (es)
HR (1) HRP20191596T1 (es)
HU (1) HUE044787T2 (es)
IL (1) IL255208A0 (es)
LT (1) LT3292133T (es)
MA (1) MA42039A (es)
MX (1) MX2017014134A (es)
PE (1) PE20180204A1 (es)
PH (1) PH12017502010A1 (es)
PL (1) PL3292133T3 (es)
PT (1) PT3292133T (es)
SG (1) SG11201708747PA (es)
SI (1) SI3292133T1 (es)
TN (1) TN2017000466A1 (es)
TW (1) TW201713651A (es)
UY (1) UY36664A (es)
WO (1) WO2016188711A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108884A1 (de) 2016-12-16 2018-06-21 Bayer Pharma Aktiengesellschaft Pharmazeutische tablettenformulierung
WO2019180072A1 (en) 2018-03-22 2019-09-26 Bayer Pharma Aktiengesellschaft Parenteral pharmaceutical composition comprising neladenoson bialanate
TWI721449B (zh) * 2019-06-11 2021-03-11 行政院原子能委員會核能研究所 2-[[2-[[[3-(4-氯苯基)-8-甲基-8-氮雜雙環[3.2.1]-辛-2-基]-甲基](2-巰基乙基)胺基]乙基]胺基]乙硫醇-[1r(外向-外向)]三鹽酸化物之純化方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Also Published As

Publication number Publication date
HK1246290A1 (zh) 2018-09-07
AU2016268920A1 (en) 2017-11-09
PT3292133T (pt) 2019-09-18
CA2984984A1 (en) 2016-12-01
SG11201708747PA (en) 2017-11-29
CU20170136A7 (es) 2018-02-08
CN107531688A (zh) 2018-01-02
TN2017000466A1 (en) 2019-04-12
BR112017023852A2 (pt) 2018-07-17
HRP20191596T1 (hr) 2019-11-29
SI3292133T1 (sl) 2019-08-30
CL2017002764A1 (es) 2018-05-25
JP2018516882A (ja) 2018-06-28
MA42039A (fr) 2018-03-14
MX2017014134A (es) 2018-03-15
IL255208A0 (en) 2017-12-31
EP3292133A1 (de) 2018-03-14
EA201792422A1 (ru) 2018-02-28
ES2744227T3 (es) 2020-02-24
WO2016188711A1 (de) 2016-12-01
PE20180204A1 (es) 2018-01-31
TW201713651A (zh) 2017-04-16
EP3292133B1 (de) 2019-06-26
DK3292133T3 (da) 2019-09-23
KR20180002698A (ko) 2018-01-08
PL3292133T3 (pl) 2019-12-31
PH12017502010A1 (en) 2018-03-26
CO2017011294A2 (es) 2018-01-16
ECSP17072780A (es) 2017-12-01
LT3292133T (lt) 2019-08-26
US20180155336A1 (en) 2018-06-07
HUE044787T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
EP3291814A4 (en) Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
EA201692219A1 (ru) Способы получения противовирусных соединений
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
BR112014003216A2 (pt) compostos, processos para preparação de compostos de fórmula i, composições agroquímicas, uso de compostos de fórmula i ou viii e uso de pelo menos um composto de fórmula i ou viii
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
EA201591085A1 (ru) Композиция с отсроченным высвобождением, содержащая бигуанид
IL239940B (en) History of 2-[3-(diazolyl)phenyl]-3,1-thiazole-5-carboxylic acid and intermediates obtained in the process for their preparation
AR095727A1 (es) Preparación de intermediarios de pirimidina
MX2015014688A (es) Tiazoles y usos de los mismos.
SG11201709593VA (en) CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
CR20160016A (es) Pirazolpiridinas sustituidas
CO2017011294A2 (es) Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
BR112016021910A2 (pt) Processo de preparação de 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h-imidazo[4,5-b]piridin-2-il)piridin-2-amina
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
AR098134A1 (es) Compuestos de urea
SG11201701674RA (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
MX2016013911A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
BR112017018248A2 (pt) composto metalorgânico
IN2013MU00777A (es)
AR104502A1 (es) Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro
WO2014125233A3 (fr) Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221114